Systemic safety analysis of mycophenolate in Graves' orbitopathy.

A C H LeeM RiedlL FrommerT DianaGeorge J Kahaly

Published in: Journal of endocrinological investigation (2019)

The risk-benefit ratio of low-dose mycophenolate treatment in active moderate-to-severe GO is highly favorable given its reassuring safety profile with low rate of mild-to-moderate SE and promising efficacy.

Keyphrases

low dose
high dose
early onset